Gaudium IVF IPO Day 3: Subscription Tops 3x, Strong GMP & Investor Views

The Gaudium IVF IPO continued to attract strong investor interest on Day 3 of its subscription period, with overall bids surpassing three times the issue size. As the public offering closes on 24 February 2026, the IPO is showing robust demand from retail and non-institutional investors, indicating positive sentiment around the fertility healthcare firm’s growth prospects. Subscription figures so far reflect broad participation, especially from individual applicants, reinforcing confidence ahead of the basis of allotment.

By midday on Day 3, the IPO had achieved an overall subscription rate exceeding 3x, led by a heavy oversubscription in the retail category. Retail investors have shown particular enthusiasm, reserving a major portion of the demand, with non-institutional investors also continuing to contribute healthy bids. Qualified institutional buyers (QIBs) have been moderately active, adding to the strong subscription trend. With only hours left in the subscription window, analysts expect final subscription figures to climb even higher before the close.

One of the most closely watched indicators of sentiment has been the grey market premium (GMP). On Day 3, Gaudium IVF’s GMP was tracking around ₹8 to ₹10 per share, suggesting that unofficial market participants anticipate a favourable listing price compared with the IPO’s price band. Given the IPO price range of ₹75 to ₹79 per share, this implied GMP indicates expectations that shares could list near ₹87 to ₹89, offering potentially healthy gains for investors subscribing at the upper band.

The IPO’s subscription timeline began on 20 February 2026 and will conclude on 24 February 2026. The basis of allotment is scheduled for 25 February 2026, with refunds processed soon after for unsuccessful applicants. Shares are expected to be credited to investors’ Demat accounts by 26 February 2026, ahead of the official listing on both the NSE and BSE on 27 February 2026. These key dates are crucial for applicants to track as they determine final allocation and market debut.

Broker views on the IPO have leaned cautiously positive. Many analysts have highlighted Gaudium IVF’s expanding footprint in the fertility services segment, driven by a network of clinics offering advanced reproductive healthcare treatments. The company’s operational model covers a range of fertility interventions, including In Vitro Fertilisation (IVF), intrauterine insemination (IUI), and other assisted reproductive procedures, meeting rising demand across India’s growing population seeking fertility solutions.

From a financial perspective, the firm has recorded consistent revenue growth and robust profitability over recent fiscal periods, strengthening investor confidence in its business fundamentals. This performance, coupled with increasing acceptance of fertility healthcare services, has made the IPO attractive to a segment of investors seeking long-term exposure to the healthcare sector.

Despite strong subscription momentum, some brokerages have advised investors to evaluate valuation levels carefully before applying. While the GMP suggests potential listing gains, long-term returns will depend on sustained earnings growth and competitive positioning within the broader healthcare market. Investors are encouraged to consider their investment horizon and risk tolerance before bidding.

The grey market trend and subscription performance through Day 3 point toward a likely oversubscribed issue and favourable debut listing. Retail enthusiasm, in particular, has been a driving force, with long queues of bids reflecting strong belief in the company’s future prospects. As the IPO subscription period approaches its close, investors will closely watch final bid multipliers and allotment details to gauge the likely performance on 27 February 2026, when Gaudium IVF shares begin trading publicly.